Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat

Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.

Pyramid, cylinder and a sphere in perfect balance
• Source: shutterstock.com

Abbott weathered the enormous challenges of 2020 with a unique diversified business structure and continuous investment in innovation.

“In normal times, [our business structure] maximizes our growth opportunities, and during the pandemic, it has been tested by a global crisis and proven to be highly resilient,” CEO Robert...

More from In Vitro Diagnostics

More from Diagnostics